Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
McKesson
Dow
Medtronic
McKinsey

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Botulinum toxin type b - Biologic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for botulinum toxin type b

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Netherlands: Ministry of Health, Welfare and SportsPhase 3
Vanderbilt University Medical CenterEarly Phase 1
Oslo University HospitalPhase 3

See all botulinum toxin type b clinical trials

Recent Litigation for botulinum toxin type b

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Halozyme, Inc. v. Lee2016-12-19

See all botulinum toxin type b litigation

Pharmacology for botulinum toxin type b

Company Disclosures: US Patents for botulinum toxin type b

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-06-10 RX company
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for botulinum toxin type b

These patents were identified by searching patent claims

Supplementary Protection Certificates for botulinum toxin type b

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
0753 Netherlands   Start Trial PRODUCT NAME: TRASTUZUMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
2008000043 Germany   Start Trial PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
00564 Netherlands   Start Trial PRODUCT NAME: BOTULINUM TOXINE; NAT. REGISTRATION NO/DATE: RVG 32957RVG 17379RVG 32958 2012270627; FIRST REGISTRATION: NL 25449 20110822
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Boehringer Ingelheim
Moodys
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.